Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 27,279 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 27,279 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 3rd, Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total value of $438,898.44.
• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $44.31 on Wednesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The company has a market cap of $2.17 billion, a P/E ratio of -21.94 and a beta of 1.04. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company’s 50-day moving average price is $47.55 and its 200-day moving average price is $43.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The business had revenue of $99.41 million during the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Mirum Pharmaceuticals by 46.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 67,375 shares of the company’s stock worth $2,628,000 after acquiring an additional 21,526 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $497,000. HealthInvest Partners AB increased its position in Mirum Pharmaceuticals by 83.9% during the third quarter. HealthInvest Partners AB now owns 138,321 shares of the company’s stock worth $5,395,000 after purchasing an additional 63,121 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after purchasing an additional 17,149 shares during the period. Finally, Loomis Sayles & Co. L P acquired a new position in Mirum Pharmaceuticals in the 3rd quarter valued at about $19,473,000.

Analyst Upgrades and Downgrades

MIRM has been the topic of a number of research analyst reports. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright lifted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Buy” and a consensus price target of $58.20.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.